Metabolism - Clinical and Experimental
Volume 56, Issue 8 , Pages 1081-1086 , August 2007

The effects of pioglitazone on cerebrovascular resistance in patients with type 2 diabetes mellitus

  • Jong Suk Park

      Affiliations

    • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
    • ,
  • Min Ho Cho

      Affiliations

    • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
    • ,
  • Kyung Yul Lee

      Affiliations

    • Department of Neurology, Yonsei University College of Medicine, Seoul, Korea
    • ,
  • Chul Sik Kim

      Affiliations

    • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
    • ,
  • Hai Jin Kim

      Affiliations

    • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
    • ,
  • Ji Sun Nam

      Affiliations

    • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
    • ,
  • Chul Woo Ahn

      Affiliations

    • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
    • Corresponding Author InformationCorresponding author. Division of Endocrinology, Department for Internal Medicine, Youngdong Severance Hospital, Yonsei University College of Medicine, Dogok-dong, Kangnam-ku, P.O. Box 135-720, Seoul 146-92, Korea. Tel.: +822 2019 3339; fax: +822 3463 3882.
    • ,
  • Bong Soo Cha

      Affiliations

    • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
    • ,
  • Sung Kil Lim

      Affiliations

    • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
    • ,
  • Kyung Rae Kim

      Affiliations

    • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
    • ,
  • Hyun Chul Lee

      Affiliations

    • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

Received 4 December 2006 ,Accepted 20 March 2007.

References 

  1. Kannel WB, McGee DL. Diabetes and cardiovascular disease; the Framingham study. JAMA. 1979;241:2035–2038
  2. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106–1108
  3. Barbier O, Torra IP, Duguay Y, et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 2002;22:717–726
  4. Martens FM, Visseren FL, Lemay J, De Koning EJ, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. Drugs. 2002;62:1463–1480
  5. Mercuri M, Bond MG, Nichos FT, et al. Baseline reproducibility of B-mode ultrasound imaging measurements of carotid intimal media thickness. J Cardiovasc Diagn Proced. 1993;11:241–252
  6. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors; the ARIC study, 1987-1993. Am J Epidemiol. 1997;146:483–494
  7. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998;128:262–269
  8. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. Cardiovascular health study collaborative research group: Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999;340:14–22
  9. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decrease carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus. Circulation. 2005;111:2525–2531
  10. Nakamura T, Matsuda T, Kawagoe Y, et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism. 2004;53:1382–1386
  11. Pfutzner A, Marx N, Lubben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol. 2005;45:1925–1931
  12. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 2001;86:3452–3456
  13. Meigs JB, Nathan DM, D'Agostino RB, Wilson PW. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care. 2002;25:1845–1850
  14. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997;14:S7–S85
  15. Wakisaka M, Nagamachi S, Inoue K, Morotomi Y, Nunoi K, Fujishima M. Reduced regional cerebral blood flow in aged noninsulin-dependent diabetic patients with no history of cerebrovascular disease: evaluation by N-isopropyl-123I-p-iodoamphetamine with single photon emission computed tomography. J Diabetes Complications. 1990;4:170–174
  16. Jimenez-Bonilla JF, Carril JM, Quirce R, Gomez-Barquin R, Amado JA, Gutierrez-Mendiguchia C. Assessment of cerebral blood flow in diabetic patients with no clinical history of neurological disease. Nucl Med Commun. 1996;17:790–794
  17. Rodriguez G, Nobili F, Celestino MA, et al. Regional cerebral blood flow and cerebrovascular reactivity in IDDM. Diabetes Care. 1993;16:462–483
  18. Mortel KF, Meyer JS, Sims PA, McClintic K. Diabetes mellitus as a risk factor for stroke. South Med J. 1990;83:904–911
  19. Grill V, Gutniak M, Bjorkman O, et al. Cerebral blood flow and substrate utilization in insulin-treated diabetic subjects. Am J Physiol. 1990;258:813–820
  20. Lee KY, Sohn YH, Baik JS, Kim GW, Kim JS. Arterial pulsatility as an index of cerebral microangiopathy in diabetes. Stroke. 2000;31:1111–1115
  21. Bonora E, Moghetti P, Zancanaro C, Cigolini M, Querena M, Cacciatori V. Estimates of in vivo insulin action in man; comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies. J Clin Endocrinol Met. 1989;68:374–378
  22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419
  23. Roberts AW, Thomas A, Rees A, Evans M. Peroxisome proliferator–activated receptor-r agonists in atherosclerosis: Current evidence and future directions. Curr Opin Lipidol. 2003;14:567–573
  24. Tham DM, Wang YX, Rutledge JC. Modulation of vascular inflammation by PPARs. Drug News Perspect. 2003;16:109–116
  25. Derosa G, Cicero AF, Gaddi A, et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract. 2005;69:5–13
  26. Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Martin J. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther. 2002;24:378–396
  27. Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 2001;24:710–719
  28. Yamanouchi T, Sakai T, Lgarashi K, Ichiyanagi K, Watanabe H, Kawasaki T. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabet Med. 2005;22:980–985
  29. Shimazu T, Inoue I, Araki N, et al. A peroxisome proliferator–activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke. 2005;36:353–359
  30. Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE. Peroxisome proliferator–activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience. 2005;130:685–696

PII: S0026-0495(07)00126-6

doi: 10.1016/j.metabol.2007.03.017

Metabolism - Clinical and Experimental
Volume 56, Issue 8 , Pages 1081-1086 , August 2007

Article Tools

* Image Usage & Resolution